Checkpoint Inhibitors in Breast Cancer - Current Status and Future Directions

Bischoff, Joachim

doi:10.1159/000486706

Cited by 10 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, therapies that target the PD-1/PD-L1 pathway have shown promising and inspiring effects with remarkably durable responses in lung tumours [76–79] and TNBCs [80]. Indeed, numerous Phase I/II clinical trials to test antibodies that target PD-1 or PD-L1 in breast cancer are ongoing [81, 82]. Several investigations displayed that low levels of PD-L1 in clinically relevant cancer can be imaged with immuno-PET using recombinant human anti-PD-L1 antibodies [83].…”

Section: From Molecular Pathology To Molecular Imaging and Vice Versamentioning

confidence: 99%

Combining Diagnostic Imaging and Pathology for Improving Diagnosis and Prognosis of Cancer

Schillaci

Scimeca

Toschi

et al. 2019

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

In the era of personalized medicine, the management of oncological patients requires a translational and multidisciplinary approach. During early phases of cancer development, biochemical alterations of cell metabolism occur much before the formation of detectable tumour masses. Current molecular imaging techniques, targeted to the study of molecular kinetics, employ molecular tracers capable of detecting cancer lesions with both high sensitivity and specificity while also providing essential information for both prognosis and therapy. On the contrary, complementary and crucial information is provided by histopathological examination and ancillary techniques such as immunohistochemistry. Thus, the successful collaboration between diagnostic imaging and anatomic pathology can represent a fundamental step in the “tortuous” but decisive path towards personalized medicine.

show abstract

Section: From Molecular Pathology To Molecular Imaging and Vice Versamentioning

confidence: 99%

Combining Diagnostic Imaging and Pathology for Improving Diagnosis and Prognosis of Cancer

Schillaci

Scimeca

Toschi

et al. 2019

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

“…CTLA-4 has become a potential therapeutic target aiming to strengthen the activity of effector T lymphocytes in the course of T cell activation. Based on encouraging data from a phase III trial on metastatic melanoma, the first CTLA-4 checkpoint inhibitor, ipilimumab, was approved by the Food and Drug Administration (FDA) in 2011 [4]. Despite being approved for only unresectable or metastatic melanoma, ipilimumab can be viewed as a promising therapeutic strategy for many cancer types, such as renal cell carcinoma (RCC) [5], non-small cell lung carcinoma (NSCLC) [6] and small cell lung cancer (SCLC).…”

Section: Introductionmentioning

confidence: 99%

Current status of the clinical use of PD-1/PD-L1 inhibitors: a questionnaire survey of oncologists in China

Zhang

Song

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: The purpose of the present study was to obtain information on the use of PD-1/PD-L1 inhibitors by oncologists in China through a national questionnaire survey. Methods: Between the 7th and 25th of July in 2019, a questionnaire designed by the Chinese Society of Clinical Oncology Immuno-Oncology (CSCO IO) Committee on the current status of the use of PD-1/PD-L1 inhibitors was distributed online and offline to cancer-related medical departments in thirty different provinces and autonomous regions of China. The national questionnaire consisted of three sections as follows: general information, current status of the application of PD-1/PD-L1 inhibitors in the clinic, and oncologists' concerns regarding utilization. Results: The valid response rate of the current status survey was 76.3%. The proportion of senior doctors (physician-in-charge or a more superior position for more than 3 years) among the respondents was relatively high (67.0% in 588). Of the respondents, 59.2% had prescribed PD-1/PD-L1 inhibitors during clinical treatment, and the most frequent reason for not prescribing these inhibitors was the choice "do not understand the mechanism and the efficacy of PD-1/PD-L1 inhibitors". In addition, 77.9% of the prescribers used the medications in an off-label situation, and the most important motivation for this use was the fact that "there were indications abroad but not domestically". In addition, 77.9% of the prescribers believed that "immunotherapy-related adverse effects could be controlled or intervened through follow-up management". The prescribers were mostly concerned about "how to identify pseudoprogression and hyperprogression" and "immunity-related adverse effects management". Conclusion: The present study highlights the current status of PD-1/PD-L1 inhibitors in China. Increasing numbers of medical oncologists are interested in PD-1/PD-L1 inhibitors, and they are in need of immunotherapy education.

show abstract

“…Immune checkpoint inhibition represents major breakthrough in the treatment of many malignancies including breast cancer. As breast cancer is also immunogenic, targeting the immune system is a promising strategy for its treatment [4,5].…”

Section: Introductionmentioning

confidence: 99%

Immunohistochemical expression of PD-L1 and MDR1 in breast tumors: association with clinico-pathological parameters and treatment outcome

et al. 2022

View full text Add to dashboard Cite

Antitumor immune evasion is a hallmark for the development and progression of cancer. Tumor cells adopt various mechanisms to escape the host immune system recognition. One such mechanism is the over expression of programmed death ligand (PD-L1), a negative T cell regulatory molecule. Because PD-L1 overexpression causes resistance to chemotherapeutic response in many cancers, herein we explored the relationship between PD-L1 and multidrug resistance protein MDR1 in breast cancer. Immunohistochemical evaluation of PD-L1 and MDR1 proteins in 194 breast cancer tissue samples were carried out. The relationship between PD-L1 and MDR1 expression on cancer cells with clinicopathological factors and prognosis was investigated. IHC showed a signi cant correlation between PD-L1 and MDR1 expression on tumor cells. Increased PD-L1 expression was also associated with lymph node status and tumor grade of the patient. Our results also revealed that the expression of PD-L1 and MDR1 was higher in TNBC subtype compared to other breast cancer subtypes. Therefore a better understanding of the molecular mechanism through which PD-1/PD-L1 pathway contribute to the chemoresistance might bring forth the prognostic signi cance of PD-L1 and selection of patients who may bene t from immunotherapy.

show abstract

Checkpoint Inhibitors in Breast Cancer - Current Status and Future Directions

Cited by 10 publications

References 36 publications

Combining Diagnostic Imaging and Pathology for Improving Diagnosis and Prognosis of Cancer

Combining Diagnostic Imaging and Pathology for Improving Diagnosis and Prognosis of Cancer

Current status of the clinical use of PD-1/PD-L1 inhibitors: a questionnaire survey of oncologists in China

Immunohistochemical expression of PD-L1 and MDR1 in breast tumors: association with clinico-pathological parameters and treatment outcome

Contact Info

Product

Resources

About